Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.66 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | SIGLEC7 | Q9Y286 | 7/20 | 0.47 |
| ▸ | CD22 | P20273 | 1/20 | 0.47 |
| ▸ | MAG | P20916 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512289 | 1.00 | NANP (0.66) | NANPSELLSELPSIGLEC7CD22 | |
| SCHEMBL30055345 | 0.90 | NANP (0.56) | NANPSIGLEC7CD22MAG | |
| SCHEMBL16151403 | 0.90 | NANP (0.56) | NANPSIGLEC7CD22MAG | |
| SCHEMBL7263212 | 0.87 | NANP (0.62) | NANPSELLSELPSIGLEC7CD22 | |
| SCHEMBL7066109 | 0.87 | NANP (0.74) | NANPSELLSELPSIGLEC7CD22 | |
| SCHEMBL13125452 | 0.87 | NANP (0.74) | NANPSELLSELPSIGLEC7CD22 | |
| SCHEMBL28106674 | 0.87 | NANP (0.62) | NANPSELLSELPSIGLEC7CD22 | |
| SCHEMBL8489507 | 0.87 | NANP (0.74) | NANPSELLSELPSIGLEC7CD22 | |
| SCHEMBL2742889 | 0.87 | NANP (0.74) | NANPSELLSELPSIGLEC7CD22 | |
| SCHEMBL28161285 | 0.87 | NANP (0.74) | NANPSELLSELPSIGLEC7CD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | claimed |
| US-12480153-B2 | Primer and probe composition for cat blood type detection, detection method, and use | SOOCHOW UNIVERSITY (CN) | 2025-11-25 | — | — | US | claimed |
| US-20250163499-A1 | PRIMER AND PROBE COMPOSITION FOR CAT BLOOD TYPE DETECTION, DETECTION METHOD, AND USE | SOOCHOW UNIVERSITY (CN) | 2025-05-22 | — | — | US | claimed |
| US-20240254533-A1 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | OCTARINE BIO APS (DK) | 2024-08-01 | — | — | US | claimed |
| EP-4347856-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES | Octarine Bio ApS (DK) | 2024-04-10 | — | — | EP | claimed |
| EP-3788023-B1 | COMPOSITE MATERIAL COMPRISING A FIBROUS REINFORCEMENT AND A POLY(PHOSPHO-SIALATE) GEOPOLYMER MATRIX - ASSOCIATED MANUFACTURING METHOD | PYROMERAL SYSTEMS (FR) | 2023-09-27 | — | — | EP | claimed |
| WO-2022248635-A2 | METHODS FOR PRODUCING TRYPTAMINE DERIVATIVES. | OCTARINE BIO APS (DK) | 2022-12-01 | — | — | WO | claimed |
| US-20220290200-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING GLYCOSYLATED CANNABINOIDS | OCTARINE BIO IVS (DK) | 2022-09-15 | — | — | US | claimed |
| EP-3976769-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING GLYCOSYLATED CANNABINOIDS | Octarine Bio IVS (DK) | 2022-04-06 | — | — | EP | claimed |
| US-20220061279-A1 | GENETICALLY MODIFIED CELLS, TISSUES, AND ORGANS FOR TREATING DISEASE | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-03-03 | — | — | US | claimed |
| US-20210230068-A1 | COMPOSITE MATERIAL COMPRISING A FIBROUS REINFORCEMENT AND A POLY(PHOSPHO-SIALATE) GEOPOLYMER MATRIX AND ASSOCIATED MANUFACTURING METHOD | PYROMERAL SYSTEMS (FR) | 2021-07-29 | — | — | US | claimed |
| EP-3788023-A1 | COMPOSITE MATERIAL COMPRISING A FIBROUS REINFORCEMENT AND A POLY(PHOSPHO-SIALATE) GEOPOLYMER MATRIX - ASSOCIATED MANUFACTURING METHOD | Pyromeral Systems (FR) | 2021-03-10 | — | — | EP | claimed |
| EP-1796457-B1 | APPARATUS FOR PROLONGING SURVIVAL OF PLATELETS | VELICO MEDICAL INC (US) | 2011-11-23 | — | — | EP | claimed |
| US-8052667-B2 | Apparatus for preparing blood cells for cold storage | VELICO MEDICAL, INC. (US) | 2011-11-08 | — | — | US | claimed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | claimed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | claimed |
| US-6949372-B2 | Engineering intracellular sialylation pathways | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-09-27 | — | — | US | claimed |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | disclosed |
| WO-2003016469-A2 | CHEMO-ENZYMATIC SYNTHESIS OF SIALYLATED OLIGOSACCHARIDES | NEOSE TECHNOLOGIES, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-1995004278-A1 | PROCESS FOR LABELLING IMMUNOGLOBULINS | Technische Universität Dresden (DE) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | NANP 874/4885SELL 3223/4885SELP 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.